Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Operating Activities | – | – | – |
| Net Income | -$78 | -$35 | -$11 |
| Dep. & Amort. | $1 | $0 | $0 |
| Deferred Tax | $0 | $0 | $0 |
| Stock-Based Comp. | $10 | $4 | $1 |
| Change in WC | -$2 | $3 | $1 |
| Other Non-Cash | $5 | $1 | $5 |
| Operating Cash Flow | -$65 | -$27 | -$3 |
| Investing Activities | – | – | – |
| PP&E Inv. | -$2 | -$2 | -$0 |
| Net Acquisitions | $0 | $0 | $0 |
| Inv. Purchases | -$381 | -$77 | $0 |
| Inv. Sales/Matur. | $210 | $0 | $0 |
| Other Inv. Act. | $3 | $0 | -$5 |
| Investing Cash Flow | -$170 | -$79 | -$5 |
| Financing Activities | – | – | – |
| Debt Repay. | $0 | $0 | $8 |
| Stock Issued | $158 | $0 | $32 |
| Stock Repurch. | $0 | -$0 | $0 |
| Dividends Paid | $0 | $0 | $0 |
| Other Fin. Act. | $64 | $145 | $0 |
| Financing Cash Flow | $222 | $145 | $40 |
| Forex Effect | $0 | $0 | $0 |
| Net Chg. in Cash | -$13 | $39 | $31 |
| Supplemental Information | – | – | – |
| Beg. Cash | $70 | $31 | $0 |
| End Cash | $57 | $70 | $31 |
| Free Cash Flow | -$67 | -$29 | -$4 |